Mutant EZH2 alters the epigenetic network and increases epigenetic heterogeneity in B cell lymphoma
PLOS Biology · 2025-06-12 · 23 (6) · e3003191
DOI: 10.1371/journal.pbio.3003191 ↗At a glance
Journal article in PLOS Biology, published online on 2025-06-12. Written by Ofir Griess and 12 co-authors. Institution: The Department of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot, Israel. Major MEDLINE topics: Epigenesis, Genetic, Gene Regulatory Networks, Lymphoma, B-Cell, Enhancer of Zeste Homolog 2 Protein. Cited 5 times so far (Crossref); 87 references. The full text is freely available (open access, CC BY 4.0). Funded by: European Research Council, Emerson Collective, The Israeli Science Foundation.
Abstract (original language)
Diffuse large B cell lymphomas and follicular lymphomas show recurrent mutations in epigenetic regulators; among these are loss-of-function mutations in KMT2D and gain-of-function mutations in EZH2. To systematically explore the effects of these mutations on the wiring of the epigenetic network, we applied a single-cell approach to probe a wide array of histone modifications. We show that mutant-EZH2 elicits extensive effects on the epigenome of lymphomas, beyond alterations to H3K27 methylations, and is epistatic over KMT2D mutations. Utilizing the single-cell data, we present computational methods to measure epigenetic heterogeneity. We identify an unexpected characteristic of mutant-EZH2, but not KMT2D, in increasing heterogeneity, shedding light on a novel oncogenic mechanism mediated by this mutation. Finally, we present tools to reconstruct known interactions within the epigenetic network, as well as reveal potential novel cross talk between various modifications, supported by functional perturbations. Our work highlights novel roles for mutant-EZH2 in lymphomagenesis and establishes new concepts for measuring epigenetic heterogeneity and intra-chromatin connectivity in cancer cells.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- The Department of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot, Israel.
- Mass Cytometry Unit, Life Sciences Core Facilities, Weizmann Institute of Science, Rehovot, Israel.
- Bioinformatics Unit, Department of Life Sciences Core Facilities, Faculty of Biochemistry, Weizmann Institute of Science, Rehovot, Israel.
- Division of Hematology, Weill Cornell Medical College, New York, New York, United States of America.
- Department of Otolaryngology-Head and Neck Surgery, Hadassah Medical Center, Jerusalem, Israel.
- Racah Institute of Physics, Hebrew University of Jerusalem, Jerusalem, Israel.
ORCID profiles: Efrat Shema
Funding
- European Research Council
- Emerson Collective
- The Israeli Science Foundation
- Israel Cancer Research Fund
- Minerva foundation
- Israeli Council for Higher Education (CHE)
- Israeli science foundation
- Ministry of Science, Technology and Space
Cite
APA
Griess, O., Furth, N., Harpaz, N., Di Bernardo, N., Salame, T. M., Dassa, B., Karagiannidis, I., Isshiki, Y., Gross, M., Melnick, A. M., Béguelin, W., Ron, G., & Shema, E. (2025). Mutant EZH2 alters the epigenetic network and increases epigenetic heterogeneity in B cell lymphoma. PLOS Biology, 23(6), e3003191. https://doi.org/10.1371/journal.pbio.3003191
Vancouver
Griess O, Furth N, Harpaz N, Di Bernardo N, Salame TM, Dassa B, et al. Mutant EZH2 alters the epigenetic network and increases epigenetic heterogeneity in B cell lymphoma. PLOS Biology. 2025;23(6):e3003191. doi:10.1371/journal.pbio.3003191
BibTeX
@article{Griess2025,
author = {Griess, Ofir and Furth, Noa and Harpaz, Nofar and Di Bernardo, Nicoletta and Salame, Tomer-Meir and Dassa, Bareket and Karagiannidis, Ioannis and Isshiki, Yusuke and Gross, Menachem and Melnick, Ari M and Béguelin, Wendy and Ron, Guy and Shema, Efrat},
title = {Mutant EZH2 alters the epigenetic network and increases epigenetic heterogeneity in B cell lymphoma},
journal = {PLOS Biology},
year = {2025},
volume = {23},
number = {6},
pages = {e3003191},
doi = {10.1371/journal.pbio.3003191}
}
EUVIMED